Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Jenner

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Blood|July 10, 2010
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic valueBrian A Walker, Paola E Leone, Laura Chiecchio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2022
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular RiskRuth M de Tute, Charlotte Pawlyn, David A Cairns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2023
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple MyelomaMartin F Kaiser, Andrew Hall, Katrina Walker, et al.
Blood|December 9, 2024
Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUSOla Landgren, Ajai Chari, Yael C Cohen, et al.
Blood|July 5, 2007
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myelomaMatthew W Jenner, Paola E Leone, Brian A Walker, et al.
Blood|August 20, 2025
Challenging the Concept of Functional High-Risk Myeloma through Transcriptional and Genetic ProfilingSina Alexandra Beer, David A Cairns, Charlotte Pawlyn, et al.
Leukemia|February 7, 2020
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)C Ola Landgren, Ajai Chari, Yael C Cohen, et al.
Leukemia|December 2, 2020
Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trialJames Croft, Sidra Ellis, Amy L Sherborne, et al.
The Lancet. Oncology|December 19, 2018
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Blood|October 31, 2018
Subclonal <i>TP53</i> copy number is associated with prognosis in multiple myelomaVallari Shah, David C Johnson, Amy L Sherborne, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Blood|July 10, 2010
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic valueBrian A Walker, Paola E Leone, Laura Chiecchio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2022
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular RiskRuth M de Tute, Charlotte Pawlyn, David A Cairns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2023
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple MyelomaMartin F Kaiser, Andrew Hall, Katrina Walker, et al.
Blood|December 9, 2024
Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUSOla Landgren, Ajai Chari, Yael C Cohen, et al.
Blood|July 5, 2007
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myelomaMatthew W Jenner, Paola E Leone, Brian A Walker, et al.
Blood|August 20, 2025
Challenging the Concept of Functional High-Risk Myeloma through Transcriptional and Genetic ProfilingSina Alexandra Beer, David A Cairns, Charlotte Pawlyn, et al.
Leukemia|February 7, 2020
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)C Ola Landgren, Ajai Chari, Yael C Cohen, et al.
Leukemia|December 2, 2020
Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trialJames Croft, Sidra Ellis, Amy L Sherborne, et al.
The Lancet. Oncology|December 19, 2018
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Blood|October 31, 2018
Subclonal <i>TP53</i> copy number is associated with prognosis in multiple myelomaVallari Shah, David C Johnson, Amy L Sherborne, et al.
Pageof 4